Vernonia amygdalina Delile extract inhibits the hepatic gluconeogenesis through the activation of adenosine-5'monophosph kinase

Biomedicine and Pharmacotherapy

Volumn 103, Issue , 2018, Pages 1384-1391

  Wu, Xiu mi ^a   Ren, Tong ^a,b   Liu, Jin Feng ^c   Liu, Yi Jun ^a   Yang, Li Chao ^a   Jin, Xin ^a  

^a XIAMEN UNIVERSITY   (China)

^b HUAQIAO UNIVERSITY   (China)

^c Xiamen Hospital of Traditional Chinese Medicine   (China)

Author keywords

AMP activated protein kinase; Gluconeogenesis; Type 2 diabetes; Vernonia amygdalina Delile

Indexed keywords

ADENOSINE 5' MONOPHOSPHATE KINASE; AMPK PROTEIN; GLUCOSE; GLUCOSE 6 PHOSPHATASE; PEPCK PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VERNONIA AMYGDALINA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; PALMITIC ACID; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); PLANT EXTRACT; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FASTING; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEP-G2 CELL LINE; IN VITRO STUDY; INSULIN RESISTANCE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BLOOD; CHEMISTRY; DIET RESTRICTION; DRUG EFFECT; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE TOLERANCE TEST; HUMAN; LIVER; METABOLISM; PATHOLOGY; PHOSPHORYLATION; VERNONIA;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; ENZYME ACTIVATION; FASTING; GLUCONEOGENESIS; GLUCOSE TOLERANCE TEST; GLUCOSE-6-PHOSPHATASE; HEP G2 CELLS; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MICE; PALMITIC ACID; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); PHOSPHORYLATION; PLANT EXTRACTS; STREPTOZOCIN; VERNONIA;

EID: 85054711845     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2018.04.135     Document Type: Article

References (26)

1. Wild, S., Roglic, G., Green, A., Sicree, R., King, H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004), 1047–1053.
2. Saini, V., Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J. Diabetes, 1, 2010, 68.
3. Gastaldelli, A., Baldi, S., Pettiti, M., Toschi, E., Camastra, S., Natali, A., Landau, B.R., Ferrannini, E., Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49 (2000), 1367–1373.
4. Hardie, D.G., Ross, F.A., Hawley, S.A., AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13 (2012), 251–262.
5. Viollet, B., Guigas, B., Leclerc, J., Hébrard, S., Lantier, L., Mounier, R., Andreelli, F., Foretz, M., AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol. 196 (2009), 81–98.
6. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 108, 2001, 1167.
7. Koo, S.-H., Flechner, L., Qi, L., Zhang, X., Screaton, R.A., Jeffries, S., Hedrick, S., Xu, W., Boussouar, F., Brindle, P., The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437 (2005), 1109–1111.
8. Committee, W.E., WHO expert committee on diabetes mellitus second report. World Health Organiz. Tech. Rep. Ser. 646 (1980), 1–80.
9. Babalola, O., Anetor, J., Adeniyi, F., Amelioration of carbon tetrachloride-induced hepatotoxicity by terpenoid extract from leaves of Vernonia amydgalina. Afr. J. Med. Med. Sci. 30 (2001), 91–93.
10. Koshimizu, K., Ohigashi, H., Huffman, M.A., Use of Vernonia amygdalina by wild chimpanzee: possible roles of its bitter and related constituents. Physiol. Behav. 56 (1994), 1209–1216.
11. Akah, P., Okafor, C., Blood sugar lowering effect of Vernonia amygdalina Del, in an experimental rabbit model. Phytother. Res. 6 (1992), 171–173.
12. Ekpo, A., Eseyin, O.A., Ikpeme, A.O., Edoho, E.J., Studies on some biochemical effects of Vernonia amygdalina in rats. Asian J. Biochem. 2 (2007), 193–197.
13. Erasto, P., Van de Venter, M., Roux, S., Grierson, D., Afolayan, A., Effect of leaf extracts of Vernonia amygdalina on glucose utilization in chang-liver, C2C12 muscle and 3T3-L1 cells. Pharm. Biol. 47 (2009), 175–181.
14. Ojieh, A.E., Okolo, A.C., Ewhre, L.O., Njoku, I.P., Igweh, J.C., Aloamaka, P.C., Glucose Enzymatic Modulation by Vernonia amygdalina in Streptozotocin-Diabetic Wistar Rats. 2016.
15. Atangwho, I.J., Yin, K.B., Umar, M.I., Ahmad, M., Asmawi, M.Z., Vernonia amygdalina simultaneously suppresses gluconeogenesis and potentiates glucose oxidation via the pentose phosphate pathway in streptozotocin-induced diabetic rats. BMC Complement. Altern. Med., 14, 2014, 426.
16. Cooke, D.W., Plotnick, L., Type 1 diabetes mellitus in pediatrics. Pediatr. Rev. 29 (2008), 374–384.
17. Yeh, G.Y., Eisenberg, D.M., Kaptchuk, T.J., Phillips, R.S., Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 26 (2003), 1277–1294.
18. Ong, K.W., Hsu, A., Song, L., Huang, D., Tan, B.K.H., Polyphenols-rich Vernonia amygdalina shows anti-diabetic effects in streptozotocin-induced diabetic rats. J. Ethnopharmacol. 133 (2011), 598–607.
19. Ong, K.W., Hsu, A., Song, L., Huang, D., Tan, B.K., Polyphenols-rich Vernonia amygdalina shows anti-diabetic effects in streptozotocin-induced diabetic rats. J. Ethnopharmacol. 133 (2011), 598–607.
20. Asante, D.B., Effah-Yeboah, E., Barnes, P., Abban, H.A., Ameyaw, E.O., Boampong, J.N., Ofori, E.G., Dadzie, J.B., Antidiabetic effect of Young and Old ethanolic leaf extracts of Vernonia amygdalina: a comparative study. J. Diabetes Res., 2016, 2016, 8252741.
21. Staehr, P., Hother-Nielsen, O., Beck-Nielsen, H., The role of the liver in type 2 diabetes. Rev. Endocr. Metab. Disord. 5 (2004), 105–110.
22. Barthel, A., Schmoll, D., Novel concepts in insulin regulation of hepatic gluconeogenesis. Am. J. Physiol.-Endocrinol. Metab. 285 (2003), E685–E692.
23. Staehr, P., Hother-Nielsen, O., Beck-Nielsen, H., The role of the liver in type 2 diabetes. Rev. Endocr. Metab. Disord. 5 (2004), 105–110.
24. Wild, S.H., Roglic, G., Green, A., Sicree, R., King, H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030: response to Rathman and Giani. Diabetes Care, 27, 2004, 2569.
25. Lochhead, P.A., Salt, I.P., Walker, K.S., Hardie, D.G., Sutherland, C., 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 49 (2000), 896–903.
26. Kim, Y.M., Kim, M.Y., Kim, H.J., Roh, G.S., Ko, G.H., Seo, H.G., Lee, J.H., Chang, K.C., Compound c independent of AMPK inhibits ICAM-1 and VCAM-1 expression in inflammatory stimulants-activated endothelial cells in vitro and in vivo. Atherosclerosis 219 (2011), 57–64.